Market Overview

BioMarin Presents Positive Phase 1/2 Data on BMN 673 in Breast Cancer at ECC 2013

BioMarin Pharmaceutical (NASDAQ: BMRN) today announced an update on the ongoing Phase 1/2 study for its poly ADP-ribose polymerase (PARP) inhibitor, BMN 673, for the treatment of solid tumors. Dr. Ramesh Ramanathan, lead investigator of the study (Medical Director, Virginia G. Piper Cancer Center - Clinical Trials, Scottsdale Health Care, Scottsdale, AZ and Clinical Professor of Medicine, TGEN & College of Medicine, University of Arizona, Phoenix, AZ), presented the data at the Late Breaking Oral Session of the the 17th ECCO – 38th ESMO – 32nd ESTRO European Cancer Congress in Amsterdam, The Netherlands.

Data Presented Today

In the most currently available data presented today from the ongoing Phase 1/2 study, among 14 gBRCA breast cancer patients treated at the dose of 1mg/day selected for the Phase 3 study, the confirmed RECIST response rate was 50% (7 confirmed objective responses: 1 complete and 6 partial). In addition, there were 5 patients with stable disease lasting at least 24 weeks for an overall clinical benefit response

See full press release

Posted-In: News Guidance Management Global

 

Related Articles (BMRN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters